Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: AB Sciex; Enzo Biochem; Sigma-Aldrich; Precision BioSciences, Cellectis; Quidel; Galapagos, AstraZeneca; Cartagenia

NEW YORK (GenomeWeb News) – AB Sciex this week said that it has expanded its commercial operations in Brazil, replacing its indirect distribution with a direct model of sales and support. The firm also has set up a customer training center in São Paulo.

Enzo Biochem disclosed in its Form 10-Q filing with the US Securities and Exchange Commission this week that it has paid $1.1 million in cash to settle litigation with Mayflower Partners, formerly known as Biomol international, which it acquired in 2008. The dispute was over the earn-out payment under the terms of the acquisition agreement. Enzo paid the $1.1 million in its fiscal second quarter ended Dec. 31.

Sigma-Aldrich said this week that it has expanded its distribution and packaging facility in Bangalore, India by 57,000 square feet and has opened a new facility in Wuxi, China to provide localized packaging and analytical services. Eric Green, VP and managing director, International of Sigma-Aldrich, said the new Wuxi facility "reinforces China as a strategic regional supply chain hub for Asia-Pacific."

Precision BioSciences this week said that it has filed a sixth patent infringement suit against French firm Cellectis for alleged infringement of US Patent No. 8,133,697. The fifth patent lawsuit was announced just last week and alleged infringement of US Patent No. 8,129,134. All of the patents at stake cover Precision Bio's Directed Nuclease Editor genome engineering technology.

Quidel this week received the CE Mark for its RSV+hMPV molecular assay for detection of respiratory syncytial virus and human metapneumovirus. The assay distinguishes between the two infections. Quidel said it is one of several forthcoming assays from its expanding line of molecular diagnostic products.

Galapagos said this week that its BioFocus and Argenta subsidiaries would use their ADME/PK tools to screen key targets of interest to AstraZeneca in its respiratory and inflammatory diseases pipeline.

Cartagenia said this week that it has partnered with the EuroEPINOMICS Rare Epilepsy Syndromes research project, a collaborative effort of more than 20 clinical groups, research teams, and genetics labs in Europe and the US studying the underlying genetics of rare epilepsy syndromes. Under the partnership, Cartagenia is making available its cloud-based BENCH platform for genomic variant storage and interpretation, clinical data collection, and genotype-phenotype correlation analysis.

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.